Earnings ·
Intelligent Bio Solutions Inc. reported full-year fiscal 2026 results ending June 30, 2026, with total revenue of $4.2…
INBSIntelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. reported full-year fiscal 2026 results ending June 30, 2026, with total revenue of $4.2 million, a 38% year-over-year increase driven by a 22% expansion in its reader installed base to 1,886 units and a 35% rise in consumable cartridge sales to over 100,000 units. Gross profit grew 64% to $2.05 million, expanding gross margin by 778 basis points to 48.63%, supported by a manufacturing transition to Syrma Johari and an optimized product mix. The company reached 502 active customers and completed clinical data collection for its FDA 510(k) submission, targeting U.S. market entry in the second half of calendar 2026. Intelligent Bio Solutions Inc. operates in the medical technology industry, providing intelligent, rapid, non-invasive drug screening solutions via fingerprint sweat analysis.